BioSpace News Archive

Jan. 3, 2018 12:00 UTC Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH Namodenoson improves steatosis, inflammation and ballooning in pre-clinical studies A Phase II study of Namodenoson is enrolling NAFLD/NASH patients PETACH TIKVA, Israel--( BUSINESS WIRE )-- Can-Fite BioPharma Lt

The retirement will be effective after the topline data release from the ongoing MEDALIST and BELIEVE Phase 3 clinical trials with luspatercept, expected to occur in the middle of this year.

W. L. Gore & Associates announced the first implant of the GORE EXCLUDER Conformable AAA Endoprosthesis in the United States.

The iStent infinite is designed for use as a standalone procedure to reduce elevated intraocular pressure (IOP) in refractory glaucoma patients.

The new CEO has over 30 years of diversified sales, marketing, and general management experience in the life sciences arena.

Omeros announced that it has reached agreement with the FDA on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in patients with IgA nephropathy (IgAN). Patient enrollment is expected to begin early next month.

Palatin expects to commence a Phase 1 single and multiple ascending dose study in the current quarter.

This approval paves the way for the company’s application to the Israel MoH for the treatment of ALS patients in Israel for a fee, under the newly introduced Hospital Exemption regulation.

This is the first out of a number of pre-defined milestones, related to the start of combination or phase II studies as part of the ADC-1013 clinical program.

NeuroRx is developing a sequential treatment regimen of NRX-100 and NRX-101, and will begin enrolling patients shortly in a Phase 2b/3 pivotal study targeting severe bipolar depression in patients with ASIB.